Genzyme Announces Positive New Data From Two Phase 3 Studies For Oral Eliglustat Tartrate For Gaucher Disease

Genzyme, a Sanofi company, recently announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news